- Country: Serbia
- Summary: Jn 130/2024 Medicines Outside the List According to Article 9 of the Regulation on the Content and Scope of the Right to Health Care from Compulsory Health Insurance and on Participation for 2024. by Parties
- RST Ref No: 112035555
- Deadline: 17 Jan 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: JN 130/2024
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Trastuzumab-deruxtecan a 100mg ampoule, Selumetinib 60x25mg capsules
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINJn 130/2024 Medicines Outside the List According to Article 9 of the Regulation on the Content and Scope of the Right to Health Care from Compulsory Health Insurance and on Participation for 2024. by Parties - Serbia Tender
The INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA, a Government sector organization in Serbia, has announced a new tender for Jn 130/2024 Medicines Outside the List According to Article 9 of the Regulation on the Content and Scope of the Right to Health Care from Compulsory Health Insurance and on Participation for 2024. by Parties. This tender is published on SerbiaTenders under RST Ref No: 112035555 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-17.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
